JP2022513050A5 - - Google Patents

Info

Publication number
JP2022513050A5
JP2022513050A5 JP2021526571A JP2021526571A JP2022513050A5 JP 2022513050 A5 JP2022513050 A5 JP 2022513050A5 JP 2021526571 A JP2021526571 A JP 2021526571A JP 2021526571 A JP2021526571 A JP 2021526571A JP 2022513050 A5 JP2022513050 A5 JP 2022513050A5
Authority
JP
Japan
Prior art keywords
muc16
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526571A
Other languages
English (en)
Japanese (ja)
Other versions
JP7627216B2 (ja
JP2022513050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061503 external-priority patent/WO2020102555A1/en
Publication of JP2022513050A publication Critical patent/JP2022513050A/ja
Publication of JP2022513050A5 publication Critical patent/JP2022513050A5/ja
Priority to JP2024173015A priority Critical patent/JP2025010150A/ja
Application granted granted Critical
Publication of JP7627216B2 publication Critical patent/JP7627216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526571A 2018-11-16 2019-11-14 ムチン-16に対する抗体およびそれを使用する方法 Active JP7627216B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024173015A JP2025010150A (ja) 2018-11-16 2024-10-02 ムチン-16に対する抗体およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768730P 2018-11-16 2018-11-16
US62/768,730 2018-11-16
PCT/US2019/061503 WO2020102555A1 (en) 2018-11-16 2019-11-14 Antibodies to mucin-16 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024173015A Division JP2025010150A (ja) 2018-11-16 2024-10-02 ムチン-16に対する抗体およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2022513050A JP2022513050A (ja) 2022-02-07
JP2022513050A5 true JP2022513050A5 (cg-RX-API-DMAC7.html) 2022-11-17
JP7627216B2 JP7627216B2 (ja) 2025-02-05

Family

ID=70731200

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526571A Active JP7627216B2 (ja) 2018-11-16 2019-11-14 ムチン-16に対する抗体およびそれを使用する方法
JP2024173015A Pending JP2025010150A (ja) 2018-11-16 2024-10-02 ムチン-16に対する抗体およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024173015A Pending JP2025010150A (ja) 2018-11-16 2024-10-02 ムチン-16に対する抗体およびそれを使用する方法

Country Status (13)

Country Link
US (2) US12168696B2 (cg-RX-API-DMAC7.html)
EP (2) EP4640698A3 (cg-RX-API-DMAC7.html)
JP (2) JP7627216B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210101235A (cg-RX-API-DMAC7.html)
CN (1) CN113366022B (cg-RX-API-DMAC7.html)
AU (2) AU2019380320B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119968A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191058A1 (cg-RX-API-DMAC7.html)
IL (1) IL283136A (cg-RX-API-DMAC7.html)
MX (2) MX2021005751A (cg-RX-API-DMAC7.html)
SG (1) SG11202105010UA (cg-RX-API-DMAC7.html)
WO (1) WO2020102555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
CN119912576B (zh) * 2023-10-31 2026-04-10 深圳华大生命科学研究院 一种ca125抗原结合蛋白及其应用
WO2025129039A1 (en) * 2023-12-14 2025-06-19 University Of Florida Research Foundation, Inc. Biosensor detection of breast cancer staging in saliva biomarkers
CN119638843B (zh) * 2024-03-20 2025-08-26 武汉勖瑞生物科技有限责任公司 一种抗ca125蛋白的单克隆抗体及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2793753C (en) * 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2013120012A2 (en) * 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
KR102618312B1 (ko) * 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
US12617866B2 (en) * 2019-05-08 2026-05-05 Memorial Sloan Kettering Cancer Center Humanized antibodies to mucin-16 and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7562528B2 (ja) 抗体及びその用途
TWI821474B (zh) Cd3抗體及其藥物用途
CN112969476B (zh) 多特异性蛋白分子
JP6669722B2 (ja) Cd3結合ドメイン
JP2019116474A5 (cg-RX-API-DMAC7.html)
CN111417653A (zh) Cd47抗原结合分子
EP3928790A1 (en) Cd3 antigen binding fragment and application thereof
WO2021139758A1 (zh) 新型多肽复合物
JP2023159379A (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
JP2020515277A5 (cg-RX-API-DMAC7.html)
WO2022171100A1 (zh) Gpc3人源化抗体及其应用
JP2021512604A5 (cg-RX-API-DMAC7.html)
WO2024175093A1 (en) Antibodies, antigen-binding fragments and methods of use
JP2024507937A (ja) Cd123及びガンマデルタt細胞受容体に結合する抗体
CN117858721A (zh) 用于治疗α-突触核蛋白病的抗体
CN111479827B (zh) 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体
CN113454120A (zh) 针对人免疫检查点CEACAM1(CD66a)的拮抗剂抗体及其制剂,试剂盒,和使用方法
EP4608864A1 (en) Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
JP2020533953A5 (cg-RX-API-DMAC7.html)
WO2024027828A1 (en) Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen
RU2802272C2 (ru) Антитело к cd3 и его фармацевтическое применение
WO2022148383A1 (en) A bispecific antibody targeting gpc3 and cd47
WO2023186078A1 (zh) 针对c-Met的抗体及其用途
HK40051452A (en) Cd3 antibody and pharmaceutical use thereof
JPWO2023153471A5 (cg-RX-API-DMAC7.html)